EPRX Eupraxia Pharmaceuticals Forecast, Technical & Fundamental Analysis
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals... Show more
EPRX is expected to report earnings to fall 2.17% to -22 cents per share on August 07
Q2'26
Est.
$-0.22
Q1'26
Missed
by $0.05
Q4'25
Missed
by $0.17
Q3'25
Missed
by $0.01
Q2'25
Missed
by $0.06
The last earnings report on May 12 showed earnings per share of -23 cents, missing the estimate of -18 cents. With 449.80K shares outstanding, the current market capitalization sits at 381.21M.
A.I.dvisor tells us that EPRX and LCTX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EPRX and LCTX's prices will move in lockstep.
EPRX in +2.89% Uptrend, rising for three consecutive days on July 22, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where EPRX advanced for three days, in of 106 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
EPRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 120 cases where EPRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EPRX as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for EPRX turned negative on July 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at .
EPRX moved below its 50-day moving average on July 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EPRX moved below the 200-day moving average on June 24, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EPRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.512) is normal, around the industry mean (19.191). P/E Ratio (0.000) is within average values for comparable stocks, (38.162). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.511). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (394.782).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EPRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EPRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
